Tamoxifen not likely to prevent many breast cancers in at-risk women
Research has shown that the drug tamoxifen citrate not only helps prevent recurrence of breast cancer, but it also can keep the deadly disease from occurring in the first place in some women.
But a new University of North Carolina at Chapel Hill study indicates its unlikely that tamoxifen will ever be given widely to women to prevent breast cancer. Thats because the drug would avert only a maximum of 6 percent to 8.3 percent of breast tumors in eligible women, UNC School of Medicine researchers have found. "Our calculations showed that tamoxifens possibly harmful side effects, including blood clots and stroke, would rule out some 90 percent of women who might benefit from taking it each day," said Dr. Russell P Harris, associate professor of medicine at UNC. A report on the study appears in the latest issue of the Archives of Internal Medicine.
Besides Harris, a member of UNCs Lineberger Comprehensive Cancer Center, authors are principal investigator Dr. Carmen L. Lewis, assistant professor of medicine at UNC; Dr. Linda S. Kinsinger, assistant director of the VA Center for Health Promotion and Disease Prevention; and Robert J. Schwartz, a computer programmer at UNCs Cecil G. Sheps Center for Health Services Research.
The study involved having 605 women, ages 40 to 69, in 10 general internal medicine practices in North Carolina, fill out questionnaires about their health and family histories of breast cancer. Then, using a proven formula for assessing breast cancer incidence and factoring in the womens responses, researchers determined the expected number of cases that would occur over the next five years.
They found that only a relatively small number of women in primary care practices would be eligible for the chemopreventive therapy because of existing conditions such as high blood pressure and diabetes and other risk factors, Harris said. Since the majority of women never develop breast cancer anyway, the percentage of actual cancers prevented would be small.
"Screening mammography, which is useful, is not the whole answer to preventing breast cancer deaths, and our new work shows that tamoxifen wont be either," he said. "On the other hand, in a message to the research community, tamoxifen has shown us that if we can find other chemopreventive agents that dont have all the side effects, then we could have greater success and save more lives."
Tamoxifen works in women by blocking whats known as the estrogen receptor that allows the hormone to work, the physician said. Most breast cancer development is dependent on estrogen.
Limitations of the research were that the number of women in each age category of the overall group were small, and black women, women with less education and those with no health insurance were not well represented in the sample, Harris said. Similar studies with larger numbers of subjects would help confirm the results.
David Williamson | EurekAlert!
The most recent press releases about innovation >>>
Die letzten 5 Focus-News des innovations-reports im Überblick:
An international team of scientists has proposed a new multi-disciplinary approach in which an array of new technologies will allow us to map biodiversity and the risks that wildlife is facing at the scale of whole landscapes. The findings are published in Nature Ecology and Evolution. This international research is led by the Kunming Institute of Zoology from China, University of East Anglia, University of Leicester and the Leibniz Institute for Zoo and Wildlife Research.
Using a combination of satellite and ground data, the team proposes that it is now possible to map biodiversity with an accuracy that has not been previously...
Heatwaves in the Arctic, longer periods of vegetation in Europe, severe floods in West Africa – starting in 2021, scientists want to explore the emissions of the greenhouse gas methane with the German-French satellite MERLIN. This is made possible by a new robust laser system of the Fraunhofer Institute for Laser Technology ILT in Aachen, which achieves unprecedented measurement accuracy.
Methane is primarily the result of the decomposition of organic matter. The gas has a 25 times greater warming potential than carbon dioxide, but is not as...
Hydrogen is regarded as the energy source of the future: It is produced with solar power and can be used to generate heat and electricity in fuel cells. Empa researchers have now succeeded in decoding the movement of hydrogen ions in crystals – a key step towards more efficient energy conversion in the hydrogen industry of tomorrow.
As charge carriers, electrons and ions play the leading role in electrochemical energy storage devices and converters such as batteries and fuel cells. Proton...
Scientists from the Excellence Cluster Universe at the Ludwig-Maximilians-Universität Munich have establised "Cosmowebportal", a unique data centre for cosmological simulations located at the Leibniz Supercomputing Centre (LRZ) of the Bavarian Academy of Sciences. The complete results of a series of large hydrodynamical cosmological simulations are available, with data volumes typically exceeding several hundred terabytes. Scientists worldwide can interactively explore these complex simulations via a web interface and directly access the results.
With current telescopes, scientists can observe our Universe’s galaxies and galaxy clusters and their distribution along an invisible cosmic web. From the...
Temperature measurements possible even on the smallest scale / Molecular ruby for use in material sciences, biology, and medicine
Chemists at Johannes Gutenberg University Mainz (JGU) in cooperation with researchers of the German Federal Institute for Materials Research and Testing (BAM)...